Novartis plans to increase use of its flagship Russian plant

20 January 2020

Swiss pharma giant Novartis (NOVN: VX) plans to increase the level of utilization of its Russian plant by almost four-fold until 2022, according to recent statements, made by representatives of the company and some St Petersburg media, reports The Pharma Letter’s local correspondent.

At present the design capacity of the company’s flagship Russian plant, which is known as Novartis Neva and which is located in the special economic zone of St Petersburg, is estimated at 1.5 billion tablets and 60 million packages per year. However, the company plans its significant expansion during the next several years.

As Leonid Shapoval, director general of Novartis Neva revealed in a recent interview with the Russian Delovoy Peterburg business paper, the process of the transfer of technologies at the plant is currently ongoing.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK